Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
Patients can now get the starting 2.5 mg dose for $299 per month
Patients can now get the starting 2.5 mg dose for $299 per month
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Subscribe To Our Newsletter & Stay Updated